Phase I study of E7010

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 2, 1998, Pages 127-134

  Yamamoto, Kaichiro ^a   Noda, Kiichiro ^a   Yoshimura, Akinobu ^b   Fukuoka, Masahiro ^a,c   Furuse, Kiyoyuki ^d   Niitani, Hisanobu ^e  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^e Tokyo Cooperative Oncology Group   (Japan)

Author keywords

Antimitotic agent; E7010; Pharmacokinetics; Phase I study; Sulfonamide

Indexed keywords

ANTINEOPLASTIC AGENT; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; ILEUS; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; AMINOPHENOLS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0031860599     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050795     Document Type: Article

References (19)

1. Yoshino H, Ueda N, Niijima J, Sugumi J, Kotake Y, Okada T, Koyanagi N, Asada M, Yoshimatsu K, Kitoh K (1992) E7010, a novel sulfonamide antitumor agent. I. Discovery and structure activity relationships. Proc Am Assoc Cancer Res 33: A3082
2. Yoshino H, Ueda N, Niijima J, Sugumi J, Kotake Y, Okada T, Koyanagi N, Asada M, Yoshimatsu K, Kitoh K (1992) Novel sulfonamides as potential, systemically active antitumor agents. J Med Chem 35: 2496
3. Koyanagi N, Nagasu T, Fujita F, Watanab T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, and Kitoh K (1992) E7010, a novel sulfonamide antitumor agent. II. In vivo antitumor activity. Proc Am Assoc Cancer Res 33: A3083
4. Koyanagi N, Nagasu T, Fujita F, Watanab T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K (1994) In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 54: 1702
5. Yoshimatsu K, Lijima A, Asada M, Kitoh K (1992) E7010, a novel sulfonamide antitumor agent. III. Mechanism of action and cell-kill kinetics. Proc Am Assoc Cancer Res 33: A3084
6. Furue H, Hara Y, Imai Y, Kimura T, Koyama Y, Kurihara M, Majima H, Nakao I, Niitani H, Ogawa M, Onoshi T, Saito T, Sakai Y, Sakano T, Sakuma A, Takaya O, Tominaga S, Yokoyama M, Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28: 101
7. Casey EB, Jelliffe AM, Le Quesne PM, Millett YL (1973) Vincristine neuropathy: clinical and electrophysiological observations. Brain 96: 69
8. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC (1993) Neurotoxicity of taxol. Monogr Natl Cancer Inst 15: 107
9. Wiemk PH, Schwartz EL, Strauman JJ et al (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47: 2486
10. Sandler SG, Tobin W, Henderson ES (1969) Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology 19: 367
11. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, Tredici G (1995) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75: 1141
12. Holmes FA, Walters RS, Theriault RL, et al (1991) Phase II trial of taxol, and an active drug in metastatic breast cancer J Natl Cancer Inst 83: 1797
13. Rowinsky EK, Burke PJ, Karp JE, et al (1989) Phase I and pharmacokinetic study of taxol in refractory acute leukemias. Cancer Res 49: 4640
14. Seewaldt VL, Greer BE, Cain JM, Figge DC, Tamini FK, Brown WS, Miller SA (1994) Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol 170: 1666
15. Seidman AW, Reichman BS, Crown JPA, Yao TJ, Currie V, Hakes TB, Hudis CL, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks E, Fain K, Souhrada M, Onetto N, Arbuck S, Norton L (1995) Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152
16. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Glabbeke V (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the clinical screening cooperative group of the European Organization for Cancer and Treatment of Cancer. J Clin Oncol 13: 314
17. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Hang WK, Raber M (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13: 645
18. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin C (1991) A phase II study of Navelbine (Vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14: 115
19. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, Ambrosini G (1994) Vinorelbine is an active anti-proliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 12: 2094